Transdermal Medical Patch Market Scope And Analysis

Report Code : TIPRE00024652
Category : Pharmaceuticals

Status : Published
No. of Pages : 194

Buy Now

Transdermal Medical Patch Market Analysis Report 2023 to 2028

Buy Now

Transdermal Medical Patch Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 8.25 Billion
Market Size by 2028	US$ 10.8 Billion
Global CAGR (2022 - 2028)	4.0%
Historical Data	2020-2021
Forecast period	2023-2028
Segments Covered	By Type Single Layer Drug-in-Adhesive Multi-layer Drug-in-Adhesive Reservoir Vapor Patch Matrix By Application Neurologic Conditions Pain Management Nicotine Cessation Cardiovascular Disorders Hormonal Therapy By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Hisamitsu Pharmaceutical Co Inc Medline Industries LP Johnson Johnson Novartis AG Teva Pharmaceutical Industries Ltd UCB SA Viatris Inc Endo Pharmaceuticals Inc Boehringer Ingelheim International GmbH

Transdermal Medical Patch Market - Recent Developments

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the transdermal medical patch market. A few recent key market developments are listed below:

In 2019, Nitto Denko Corporation announced the Bisono Tape 2mg, transdermal patches containing a β1 blocker that was co-developed with Toa Eiyo Ltd., launched by Toa Eiyo and Astellas Pharma Inc.
In June 2022, Hisamitsu Pharmaceutical Co., Inc. has been approved for the additional indications of “low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis” for ZICTHORU Tapes, transdermal, pain treatment NSAID patch in Japan. The product was approved for manufacturing and marketing approval for “analgesia in various cancer” in March 2021. This approval is based on the data of Phase III clinical studies that evaluated the efficacy and safety of the product in patients with low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis. With this approval of the additional indications, Hisamitsu expects the product to be a new option for the treatment of low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis.
In January 2021, Hisamitsu Pharmaceutical Co., Inc. has commenced the Phase III clinical study in the U.S. for transdermal, pain relief and anti-inflammatory patch for the treatment of Osteoarthritis knee pain. The clinical study will be conducted by the U.S. subsidiary, Noven Pharmaceuticals, Inc. The investigational product is a transdermal formulation developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology. Hisamitsu Pharmaceutical hopes the investigational product will be a new treatment option for Osteoarthritis of the knee, demonstrating efficacy and safety by achieving higher drug delivery to the affected area as one of the transdermal formulation attributes.
In September 2022, Corium, Inc launched ADLARITY (donepezil transdermal system) and is now available for prescription in the U.S. for treating patients with mild, moderate, or severe dementia of Alzheimer's type.